Opinion|Videos|January 9, 2025
MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
Panelists discuss how long-term follow-up data from MajesTEC-1 demonstrates teclistamab’s sustained efficacy and safety profile while identifying optimal candidates based on factors like prior therapy exposure, disease characteristics, and fitness level.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab
- Is there a patient population who would benefit most from this treatment regimen?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases
5